Home » Newsletters » BioWorld Science

BioWorld Science

May 31, 1999

View Archived Issues

EntreMed announces sites for Endostatin phase I clinical trials

Lynx and Oxagen announce SNP collaboration

Redox receives Phase II SBIR grant for genital herpes prophylactic

Noven's transdermal patch for ADHD Rx shows promise in initial clinical study

Ilex reports progress on Campath development at annual meeting

Ontogeny and Oxford Asymmetry announce lead optimization collaboration

Novartis to launch Biomatrix's Synvisc in Mexico and Peru

Genistein may offer protection against ALS and stroke

Stockholders approve VIMRx name change

Ilex initiates clinical testing of vitamin D3 analogue

Abgenix uses XenoMouse technology to generate new antibody for immunologic diseases

Chugai reviews progress of selected product candidates at end of fiscal year

AGI-1067, a new vascular protectant, advances through the development pipeline

OSI Pharmaceuticals expands Anaderm program with Pfizer

Zadaxin receives approval in Malaysia for treatment of hepatitis B

AnorMED initiates phase II clinical trial for HIV therapy

GW-0072, a novel PPARgamma receptor ligand with unique biological activities

Study of WR-6026 in HIV-infected patients supports clinical utility in treating PCP

Fragmin approved in U.S. for treatment of unstable angina and non-Q wave MI

Menarini's chiral NSAID launched in U.K.

CPMP recommends expanded approval of Temodal for brain tumor therapy

Recombinant enzyme plus gene therapy: a unique combination therapy for cancer

Potent and selective 5-HT1A receptor agonists developed at Pierre Fabre

Dual antagonists at 5-HT3 and 5-HT4 receptors for GI disorders

Roche discloses new bicyclic compounds as p38 MAP kinase inhibitors

Lilly discovers arylpiperazines acting as both 5-HT reuptake inhibitors, 5-HT1D antagonists

Novel compounds for vitamin D-dependent disorders in development at Roche

Alpha-aryl-N-alkylnitrones from Centaur useful for neurological, autoimmune, inflammatory disorders

New, highly selective I1 receptor ligand with blood pressure-lowering effects

Enol metabolite of tasosartan appears not to contribute to pharmacodynamic effects

Bosentan may represent new strategy for preventing cardiac and renal complications of hypertension

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...